| Overview of Adverse Events | | | | |
| Treatment emergent adverse events, by primary system organ class and preferred term | | | | |
| Treatment-Emergent Adverse Events by Severity | | | | |
| Treatment-Emergent Adverse Events by descending frequency | | | | |
| Treatment-Emergent Adverse Events by descending frequency - SOC repeated on page | | | | |
| Treatment-Emergent Adverse Events by descending frequency - SOC repeated - approach 2 | | | | |
| Treatment-Emergent Adverse Events by Relationship to Study Drug | | | | |
| Treatment-Emergent Adverse Events by Preferred Term | | | | |
| Treatment-Emergent Adverse Events by Preferred Term | | | | |
| Treatment-Emergent Adverse Events by Preferred Term (descending frequency) | | | | |
| TEAE That Equal to or Exceed a Threshold of 5% in Any Treatment Group | | | | |
| Treatment-Emergent Adverse Events by Preferred Term - with fisher exact test p-value | | | | |
| TEAE by PT - with chisq/fisher exact test p-value | | | | |
| TEAE by PT - Odds Ratio | | | | |
| TEAE by PT - Odds Ratio with p-value | | | | |
| TEAE by PT - Risk Ratio | | | | |
| TEAE by PT - Risk Difference | | | | |
| Exposure Adjusted Event Rate by SOC and PT | | | | |
| Exposure Adjusted Subject Incidence Rate by SOC and PT | | | | |
| TEAE by SOC, PT and Grade | | | | |